Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 30 clinical trials
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC (ADAPTcycle)

The study investigates, whether the patient group with intermediate-risk early breast cancer benefits from treatment with ribociclib in combination with endocrine therapy compared to standard-of

endocrine therapy
neutrophil count
breast cancer
hormone therapy
luminal
  • 0 views
  • 15 Feb, 2022
  • 1 location
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer (RIBOLARIS)

efficacy of a non-chemo treatment in patients biologically responders to neoadjuvant ribociclib and letrozole. This study aims to evaluate whether chemotherapy could be avoided for initial high-risk

  • 0 views
  • 17 Jun, 2022
  • 11 locations
Ribociclib and Letrozole Treatment in Ovarian Cancer

The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.

  • 152 views
  • 26 Mar, 2022
  • 27 locations
[18F]Fluorothymidine (FLT) PET/CT Imaging In Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 And Weekly Paclitaxel Therapy

Patients with a history of metastatic breast cancer who are candidates for participation in the companion therapeutic trial, UPCC 06115 "A Phase I Trial of Ribociclib (LEE011) and Weekly

erbb2
paclitaxel
HER2
advanced breast cancer
  • 15 views
  • 08 Nov, 2020
  • 1 location
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) (HERMIONE-7)

The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2- advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment for their metastatic disease. Patients will receive aromatase inhibitors plus Abemaciclib.

her2-negative breast cancer
cish
measurable disease
metastasis
estrogen
  • 39 views
  • 25 Mar, 2022
  • 38 locations
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

This study is a Phase Ib, multi-center, open-label study of TNO155 in combination with spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in adult subjects

EGFR
measurable disease
KRAS
solid tumour
ki-ras
  • 19 views
  • 11 Apr, 2022
  • 8 locations
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

, estrogen receptor (ER)-positive, HER2-negative breast cancer who had disease progression during or following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; e.g., palbociclib, ribociclib

  • 0 views
  • 20 Jun, 2022
  • 25 locations
Ribociclib (LEE011) Rollover Study for Continued Access

This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis

  • 52 views
  • 15 Jun, 2022
  • 3 locations
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

In the proposed trial, patients will be administered ribociclib prior to surgical resection of their tumor. Patients will be enrolled in time-intervals sequentially (non-randomized). All

alopecia
potassium
neutrophil count
ribociclib
liver metastases
  • 250 views
  • 27 Jan, 2022
  • 1 location
Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts (LEANORA)

The aim is to determine the pharmacological and biochemical association between ribociclib exposure and CYP3A variants in African American/Blacks and Non-Hispanic White patients. The

mammogram
endocrine therapy
hormone therapy
letrozole
fulvestrant
  • 0 views
  • 06 Mar, 2022
  • 4 locations